June 16, 2020 -- Immunomic Therapeutics (ITI) has signed a licensing agreement with Ichor Medical Systems to support the development of its ITI-1001 investigational plasmid DNA vaccine therapy.
ITI will use Ichor's TriGrid electroporation delivery technology to increase the cellular uptake of ITI-1001 when administered to patients with newly diagnosed glioblastoma multiforme (GBM). ITI-1001 is designed to target the pp65, ie-1, and gB viral antigens of cytomegalovirus (CMV), which are expressed in GBM, but not in normal brain cells, according to the company.
The first in-human phase I study for ITI-1001 is expected to begin in 2021.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
